The University of Chicago Header Logo

Connection

Rita Nanda to Bevacizumab

Back to Details
This is a "connection" page, showing publications Rita Nanda has written about Bevacizumab.
Rita Nanda
Connection Strength
0.042
Bevacizumab
  1. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. Breast Cancer Res. 2020 02 18; 22(1):22.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.